Other languages Cantargia AB

Equities

CANTA

SE0006371126

Market Closed - Nasdaq Stockholm Other stock markets 04:29:40 30/04/2024 pm IST			5-day change	1st Jan Change
3.336 ^SEK	-2.74%		-10.56%	-10.75%

17/04	Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition	CI
10/04	Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition	17/04
Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	10/04
Cantargia AB Presents Unique Effects of Nadunolimab in Pancreatic Cancer	09/04
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis	02/04
Cantargia AB Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia	27/03
Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis	14/03
Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer	06/03
Cantargia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	22/02
Cantargia Secures US Approval to Start Patient Recruitment for Pancreatic Cancer Therapy	20/02
Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab	20/02
Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy	12/02
Cantargia Reports Phase I Clinical Progress in the CAN10 Project	09/01
Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10	24/11
Cantargia Maintains Patent for Cancer Treatment Amid Withdrawal of Third-party Appeal	20/11
Cantargia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Cantargia Seeks SEK59 Million from Share Sale	31/23/31
Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer	28/23/28
Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR	20/23/20
Cantargia's Investigational Blood Cancer Drug Wins $1.1 Million External US Grant	18/23/18
Cantargia AB Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant	18/23/18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cantargia AB

Equities

CANTA

SE0006371126

Other languages

Filters